Prognostic Value of the Triglyceride-Glucose Index Combined with Non-HDL-C/HDL-C Ratio for Predicting Coronary Microvascular Dysfunction in ACS Patients Post-PCI.

Sitong Hang, Nan Tang, Kangming Li, Qingdui Zhang, Ji Hao, Yan Zhang, Chunmei Qi
Author Information
  1. Sitong Hang: China Medical University, Shenyang, Liaoning, 110000, People's Republic of China.
  2. Nan Tang: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
  3. Kangming Li: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
  4. Qingdui Zhang: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
  5. Ji Hao: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
  6. Yan Zhang: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
  7. Chunmei Qi: Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. ORCID

Abstract

Background: Coronary microvascular dysfunction (CMD) after percutaneous coronary intervention (PCI) is a critical prognostic factor in acute coronary syndrome (ACS). This study aimed to evaluate the combined predictive value of the triglyceride-glucose index (TyG) and non-HDL-C/HDL-C ratio (NHHR) for CMD in ACS patients post-PCI.
Methods: A retrospective analysis of 542 ACS patients undergoing PCI (2021-2023) was conducted. Patients were classified into CMD (n=273) and non-CMD (n=269) groups based on CMD presence post-PCI. Baseline characteristics and biochemical markers were analyzed. TyG index and NHHR were calculated, and univariate and multivariate analyses were performed to identify predictors of CMD. ROC curves evaluated the predictive value of TyG combined with NHHR, while net reclassification index (NRI) and integrated discrimination improvement (IDI) assessed incremental predictive value.
Results: CMD patients exhibited significantly higher levels of TyG and NHHR compared to non-CMD patients. Multivariate logistic regression indicated that TyG (OR = 1.89, 95% CI: 1.24-2.88, = 0.003) and NHHR (OR = 1.34, 95% CI: 1.11-1.62, = 0.011) were independent predictors of CMD. The combined model showed significant improvement in discrimination (C-statistic increased from 0.750 to 0.782, < 0.001) and reclassification (NRI = 0.458, IDI = 0.051, both < 0.001).
Conclusion: TyG and NHHR are novel predictors of CMD post-PCI, with combined use improving risk stratification. Given the retrospective nature of the study, further multicenter prospective research is required to validate these findings.

Keywords

References

  1. Lipids Health Dis. 2022 Dec 10;21(1):135 [PMID: 36496414]
  2. Clin Cardiol. 2024 Feb;47(2):e24243 [PMID: 38402557]
  3. Acta Cardiol Sin. 2024 Jul;40(4):367-372 [PMID: 39045366]
  4. Biomark Med. 2023 Jan;17(1):29-39 [PMID: 36994674]
  5. Cardiovasc Diabetol. 2022 May 6;21(1):68 [PMID: 35524263]
  6. Diab Vasc Dis Res. 2022 Sep-Oct;19(5):14791641221136203 [PMID: 36270638]
  7. JAMA. 2022 Feb 15;327(7):662-675 [PMID: 35166796]
  8. JAMA. 2024 Jun 4;331(21):1834-1844 [PMID: 38607340]
  9. Int Urol Nephrol. 2024 Aug;56(8):2793-2802 [PMID: 38536621]
  10. Eur J Cardiothorac Surg. 2023 Aug 1;64(2): [PMID: 37632766]
  11. Cardiovasc Diabetol. 2023 Jun 9;22(1):133 [PMID: 37296406]
  12. Diagnostics (Basel). 2024 Oct 11;14(20): [PMID: 39451584]
  13. Curr Atheroscler Rep. 2023 Aug;25(8):435-446 [PMID: 37338666]
  14. Front Physiol. 2024 Aug 13;15:1398793 [PMID: 39193442]
  15. JAMA Cardiol. 2024 Sep 1;9(9):770-780 [PMID: 38922632]
  16. Acta Cardiol Sin. 2024 Jul;40(4):388-401 [PMID: 39045373]
  17. Endocrine. 2022 Feb;75(2):392-399 [PMID: 34542800]
  18. Circulation. 2021 Jul 13;144(2):e16-e35 [PMID: 34126755]
  19. Front Cardiovasc Med. 2024 Jun 17;11:1396865 [PMID: 38952542]
  20. Lipids Health Dis. 2022 Nov 11;21(1):118 [PMID: 36369093]
  21. Sci Rep. 2024 Aug 28;14(1):19959 [PMID: 39198550]
  22. Int J Obes (Lond). 2024 May;48(5):662-667 [PMID: 38302591]
  23. J Clin Med. 2024 Aug 16;13(16): [PMID: 39200973]
  24. Nutr Metab Cardiovasc Dis. 2024 Jan;34(1):107-111 [PMID: 37949711]
  25. MedComm (2020). 2023 Dec 19;4(6):e438 [PMID: 38116064]
  26. J Clin Med. 2024 Oct 09;13(19): [PMID: 39408068]

Word Cloud

Created with Highcharts 10.0.0CMD0NHHRTyG=coronaryACScombinedindexpatients1predictivevaluepost-PCIpredictorsCoronarymicrovasculardysfunctionpercutaneousinterventionPCIacutesyndromestudytriglyceride-glucoseretrospectivePatientsnon-CMDreclassificationNRIdiscriminationimprovementIDIOR95%CI:<001Background:criticalprognosticfactoraimedevaluatenon-HDL-C/HDL-CratioMethods:analysis542undergoing2021-2023conductedclassifiedn=273n=269groupsbasedpresenceBaselinecharacteristicsbiochemicalmarkersanalyzedcalculatedunivariatemultivariateanalysesperformedidentifyROCcurvesevaluatednetintegratedassessedincrementalResults:exhibitedsignificantlyhigherlevelscomparedMultivariatelogisticregressionindicated8924-2880033411-162011independentmodelshowedsignificantC-statisticincreased750782458051Conclusion:noveluseimprovingriskstratificationGivennaturemulticenterprospectiveresearchrequiredvalidatefindingsPrognosticValueTriglyceride-GlucoseIndexCombinedNon-HDL-C/HDL-CRatioPredictingMicrovascularDysfunctionPost-PCI

Similar Articles

Cited By

No available data.